1. EachPod

Episode 3: PAD - Endovascular Interventions

Author
Yale Vascular Surgery
Published
Mon 29 Nov 2021
Episode Link
https://rss.com/podcasts/yalevascularreview/328112

Hosts: Ocean Setia is a PGY-4 Vascular Surgery Integrated Resident. Keyuree Satam is a 4th year medical student at Yale.

Papers:

Twenty-Four-Month Outcomes of Drug-Coated Balloon in Diabetic Patients in the BIOLUX P-III Registry: A Subgroup Analysis

Cost Effectiveness of Primary Stenting in the Superficial Femoral Artery for Intermittent Claudication: Two Year Results of a Randomised Multicentre Trial

Long-term safety and efficacy of angioplasty of femoropopliteal artery disease with drug-coated balloons from the AcoArt I trial

Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization

Effects of Exercise Mode on Arterial Stiffness in Symptomatic Peripheral Artery Disease Patients: A Randomized Crossover Clinical Trial

PROMISE I: Early feasibility study of the LimFlow System for percutaneous deep vein arterialization in no-option chronic limb-threatening ischemia: 12-month results

Impact of impaired ambulatory capacity on the outcomes of peripheral vascular interventions among patients with chronic limb-threating ischemia

Revascularization of intermittent claudicants leads to more chronic limb-threatening ischemia and higher amputation rates

Pedal Acceleration Time (PAT): A Novel Predictor of Limb Salvage

Use of drug-eluting stents in patients with critical limb ischemia and infrapopliteal arterial disease: a real-world single-center experience

A Comparison of Outcomes Based on Vessel Type (Native Artery vs. Bypass Graft) and Artery Location (Below-Knee Artery vs. Non-Below-Knee Artery) Using a Combination of Multiple Endovascular Techniques for Acute Lower Limb Ischemia

Comparison between antegrade common femoral artery access and superficial femoral artery access in infrainguinal endovascular interventions

Follow Us: Twitter @YaleVascular, Instagram @yalevascular

Email: [email protected], [email protected]

Share to: